HER2 is a protein that can cause a more aggressive form of breast cancer. What to know if your doctor tells you that you have "HER2-positive" breast cancer.

Before targeted therapies like trastuzumab, patients with HER2-positive lung cancer had limited options apart from standard chemotherapy, with generally poor outcomes and greater side effects.

Medically reviewed by Lindsay Cook, PharmD If you have HER2-positive breast cancer, your options for treatment will depend on several factors, such as the stage of cancer (early or metastatic) and ...

HER2-positive breast cancer is a fast-growing type. Learn about its symptoms, causes, treatment, and prevention options. Early detection and targeted therapy can lead to a cure.

Published in npj Breast Cancer, the study combined the HER2-targeting dendritic cell vaccines with standard chemotherapy, demonstrating both safety and positive response rates.

Drugs designed to target HER2-postive breast cancer could also benefit some patients with bile duct cancer, according to results of a patient trial to be presented on Thursday at the 36th EORTC ...

A new study led by investigators from Mass General Brigham trialed stereotactic (targeted) brain-directed radiation in 100 ...

Trastuzumab itself is a mainstay treatment of HER2-positive breast cancer that has spread to other parts of the body, including the brain.

However, patients with HER2-positive metastatic bile duct cancer and HER2-mutated metastatic breast cancer experienced clinically relevant overall response rates.

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive metastatic breast cancer.

Arturo Loaiza-Bonilla, MD, MSEd, systemwide chief of hematology and oncology at St. Lukes University Health Network and ...

There were no cases of HER2 positivity among patients with gliomas, sarcomas, small cell lung cancer, gastrointestinal stromal tumors, thyroid carcinoma, uterine sarcoma, thymic carcinoma, and Merkel ...